Shandong Yidu Biotechnology

Shandong Yidu Biotechnology is a Chinese biopharmaceutical company specializing in the research, development, and large-scale production of human vaccines. Founded in 2012 and headquartered in Dongying, Shandong, the company is a key subsidiary of the Chongqing Yidu Biotechnology Group. Its flagship product, a freeze-dried human rabies vaccine (Vero cell), was developed using advanced bioreactor microcarrier technology and received NMPA approval in 2021. The company's R&D pipeline includes high-valency candidates such as a 20-valent pneumococcal conjugate vaccine (PCV20) and a five-valent rotavirus vaccine. Yidu operates a modern GMP-certified manufacturing facility with an annual capacity of 25 million doses, positioning itself as a significant player in China's domestic vaccine market.